Skip to main content

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:

2024 Wedbush PacGrow Healthcare Conference
Tuesday, August 13, 2024, at 2:30 p.m. ET

Canaccord Genuity 44th Annual Growth Conference
Wednesday, August 14, 2024, at 12:30 p.m. ET

A live webcast of the Canaccord Genuity 44th Annual Growth Conference presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contact:

Investors:
888-969-7879                                        
IR@travere.com
Media:
888-969-7879                                        
mediarelations@travere.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  203.69
-6.42 (-3.06%)
AAPL  266.34
+1.76 (0.67%)
AMD  196.00
-4.16 (-2.08%)
BAC  51.05
-2.01 (-3.78%)
GOOG  313.68
-1.22 (-0.39%)
META  642.90
-12.76 (-1.95%)
MSFT  385.71
-11.52 (-2.90%)
NVDA  190.82
+1.00 (0.53%)
ORCL  139.15
-8.93 (-6.03%)
TSLA  398.17
-13.65 (-3.31%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.